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alaria remains the most 
important parasitic disease 
affecting humans [1]. Every 
year, there are some 5 billion clinical 
episodes resembling malaria, some 
600 million clinical malaria cases, and 
about 1 million malaria deaths [2]. The 
great majority of the malaria burden 
falls on the poor rural communities in 
sub-Saharan Africa (SSA), and most 
deaths occur in young children [1,2]. 
Malaria is considered a major barrier to 
the development of SSA [3].
The rapid spread of resistance 
against chloroquine, for decades the 
most important safe, effective, and 
affordable antimalarial drug worldwide, 
was considered a public health disaster 
for SSA by 1998 [4]. One year later, 
a group of leading malariologists 
called for the systematic employment 
of combination therapy, preferably 
artemisinin-based combination 
therapy (ACT), to avert the further 
spread of drug resistance and thus 
a global malaria catastrophe [5]. 
In the meantime, the grave public 
health consequences of chloroquine 
resistance in terms of increasing 
childhood mortality in SSA have been 
well described [6,7]. As a consequence, 
23 countries in SSA had changed their 
ﬁ  rst-line malaria treatment policy to 
ACT by the end of 2004, and many 
more have followed up to the present 
[8]. However, because of its cost and 
short supply, ACT remains ﬁ  rst-line 
therapy in policy but not in practice 
[1,9,10].
In the ﬁ  eld of malaria prevention, 
insecticide-treated mosquito nets (ITNs) 
have been developed as a promising 
tool over the last two decades [1]. ITN 
protection is roughly associated with a 
50% reduction of malaria morbidity and 
a 20% reduction of all-cause mortality in 
children, and these effects are sustained 
over time [11,12]. However, 25 years 
after the ﬁ  rst report on the beneﬁ  t 
of this intervention, ITN coverage in 
young children is still unacceptably low 
in SSA [13].
Here we present an analysis of the 
malaria situation in one typical district 
of Burkina Faso, which likely represents 
the pattern of problems seen in many 
SSA countries today.
Health Services and Research 
Capacity
Burkina Faso, situated in the Sahel 
zone of West Africa, is one of the 
poorest countries in the world 
[14]. State and external aid cover 
respectively 18% and 28% of all health 
expenditure; the remaining 54% is 
ﬁ  nanced directly by the population 
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[14]. Governmental health spending 
equals US$9 per capita per year. A 
total of three teaching hospitals, 11 
regional hospitals, and 55 district 
hospitals serve the country. While the 
regional hospitals have specialist units 
and are run by physicians, the district 
hospitals are run by nurses with some 
supervision, usually from two physicians 
in charge of the whole district. 
Consequently, formal health services 
for the rural population are limited 
to small health centres staffed by two 
nurses and one midwife.
The National Malaria Control 
Programme (NMCP) is a rather 
small Ministry of Health unit (three 
physicians, seven other staff). In 
contrast, four research centres in 
the country are engaged in malaria 
research: The Centre National de 
Recherche et de Formation sur 
le Paludisme and the Institut de 
Recherche en Sciences de la Santé 
in the capital city Ouagadougou, the 
Centre Muraz in Bobo Dioulasso, 
and the Centre de Recherche en 
Santé de Nouna in Nouna (Figures 
1 and 2). These centres receive 
various external support ranging 
from academic collaborations to long-
standing capacity-building grants from 
industrialised countries. Overall, some 
50 scientists are working on malaria in 
these institutions.
Malaria in Burkina Faso
Malaria in Burkina Faso, predominantly 
caused by Plasmodium falciparum, is 
highly endemic and the leading cause 
for morbidity and mortality [15,16]. 
In vivo chloroquine resistance was ﬁ  rst 
reported in 1988 and clinical failure 
rates in children with uncomplicated 
malaria were around 5% in the early 
1990s [17]. However, more recent 
data have shown a rapid increase of 
chloroquine but not pyrimethamine–
sulfadoxine resistance over the last few 
years [18–21].
In February 2005, the Ministry of 
Health called for a national expert 
meeting to discuss alternative malaria 
treatment options. It was decided to 
switch from chloroquine to ACT and 
this information was circulated to all 
governmental health workers by April 
2005 [22]. In a further correspondence 
to the formal health services, this 
policy change was reinforced by the 
Ministry of Health in June 2006 despite 
mention in the same document that 
ACT was still not available through 
governmental drug channels [23].
Malaria in the Nouna Health 
District
Nouna Health District (NHD) is 
situated in north-western Burkina 
Faso. It has a population of 296,000 
living in 274 villages served by 25 local 
health centres and by a district hospital 
located in the provincial capital, Nouna 
(population 25,000). 
Malaria is holoendemic but highly 
seasonal in NHD, with most cases 
occurring during or brieﬂ  y after the 
rainy season, which lasts from June 
until October [15]. Most of the malaria 
burden is in children, with preschool 
children experiencing at least six fever 
episodes and two malaria episodes per 
year [16]. Malaria is the major cause for 
the childhood mortality rate of 35 per 
1,000 per year [24,25]. Chloroquine 
treatment of preschool children in 
2001 failed in 10% on day 14, but 
failure rates subsequently increased 
signiﬁ  cantly ([26] and B. Kouyaté, 
unpublished data). In 2003, this ﬁ  gure 
was above 50% in Nouna town [21]. 
Malaria control is based on home 
treatment of fever cases with a mix 
of antipyretics, chloroquine, and 
traditional treatments [27]. Only a 
minority of patients are treated in 
formal health services [27], and many 
antimalarials are substandard drugs 
bought at markets. The great majority 
of children who die of malaria had not 
visited formal health services during 
their ﬁ  nal illness [27]. 
On average and considering 
exclusively direct costs, households in 
NHD spend about US$2 to treat one 
fever episode [28]. Considering that a 
child suffers about six episodes of fever 
per year, an average household with 
four children may end up spending 
US$48 just for presumptive malaria 
treatment in children. 
In spite of the ofﬁ  cial policy change, 
ACT continues to be available only 
in private pharmacies in the town of 
Nouna and at a prohibitively high price 
(US$6.5 for the course of treatment 
needed for a child). A study conducted 
in early 2006 on a representative 
sample of 1,080 NHD households 
demonstrated that of 122 fever episodes 
doi:10.1371/journal.pmed.0040127.g002
Figure 2. Location of the Four Malaria Research Centres in Burkina Faso 
The four centres are the Centre National de Recherche et de Formation sur le Paludisme and the 
Institut de Recherche en Sciences de la Santé in the capital city Ouagadougou, the Centre Muraz in 
Bobo Dioulasso, and the Centre de Recherche en Santé de Nouna in Nouna. 
(Figure: Anthony Flores)
June 2007  |  Volume 4  |  Issue 6  |  e127PLoS Medicine  |  www.plosmedicine.org 0999
in preschool children, none was treated 
with ACT, 112 were treated with 
chloroquine, six with amodiaquine, 
three with quinine, and one with 
pyrimethamine  –sulfadoxine (M. Tipke, 
unpublished data). This treatment 
behaviour may also be inﬂ  uenced by 
the experience of chloroquine being 
a good anti-inﬂ  ammatory drug in 
cases of febrile illness. However, even 
governmental health workers in Nouna 
town are still prescribing chloroquine 
for the treatment of fever in young 
children. 
ITN provision in the NHD was until 
recently limited to project activities 
at the Centre de Recherche en Santé 
de Nouna and to small-scale sales 
supported by social marketing in 
Nouna town [12]. However, it has 
been shown that demand for ITNs is 
high and that compliance with freely 
distributed ITNs under the conditions 
of an effectiveness trial was good 
[29,30].
Discussion
The difﬁ  culties of translating research 
ﬁ  ndings into practice are well known 
and have been found to be a universal 
phenomenon [31]. With regard to 
evidence-based changes of malaria 
treatment policies, such processes have 
already been described in detail for 
selected SSA countries [32,33].
The development of clinically 
relevant resistance against chloroquine 
in Burkina Faso was discovered through 
studies conducted by national health 
research centres. This was followed by 
a national meeting of experts and—
forced by strong recommendations 
from the World Health Organization 
(WHO)—to a policy shift to ACT as 
recommended treatment. However, for 
the last two years this policy has been 
only on paper as ACT is not available 
through governmental health services. 
The obvious reason for this is lack of 
funds. The Global Fund to Fight AIDS, 
Tuberculosis and Malaria (GFATM) 
is the main external funding body 
for ACT in SSA [1,34]. However, a 
proposal to the GFATM on malaria 
control support in Burkina Faso was 
rejected in June 2005. This decision 
is widely perceived in Burkina Faso as 
mainly motivated by ﬁ  nancial problems 
of the GFATM.
Another obvious fact is that malaria 
research capacity appears to be well 
developed in Burkina Faso. However, 
the implementation capacity of the 
NMCP is not. As we are aware of similar 
mismatches between research and 
implementation capacities in other SSA 
countries, we may question whether 
the tendency of external donors and 
malaria-endemic countries to invest 
much into malaria research, while at 
the same time neglecting support for 
capacity building and strengthening of 
national programmes, is justiﬁ  ed. 
So what would an ideal malaria 
control programme look like in a 
country such as Burkina Faso? First 
of all, safe and effective drugs need 
to be available and accessible to the 
whole population. High treatment 
coverage with well-equipped health 
services is unlikely to be implemented 
in the near future, particularly in 
the rural parts of the country. One 
approach to overcome this obstacle 
could be a programme of home- and 
community-based malaria treatment, 
and promising experience on this topic 
has been demonstrated (B. Kouyaté, 
unpublished data), [35]. However, the 
choice of drugs is crucial and the cost 
could be prohibitive: if all the roughly 
20 million annual fever episodes 
occurring in preschool children in 
Burkina Faso were treated with ACT at 
a cost of US$1 per course, this would 
already amount to US$20 million [2]. 
Moreover, protection of all preschool 
children with long-lasting ITNs would 
add another US$20 million as initial 
investment costs followed by US$5 
million per year for replacements 
[2,36].
Nevertheless, policy makers must 
realise that malaria prevention and 
treatment interventions clearly 
belong together, as ITN protection 
for example would roughly halve 
the number of malaria episodes and 
consequently ACT treatment courses 
[11]. An estimated US$2–3 billion 
of external funds would be needed 
every year to scale up the response 
against malaria in all of SSA, but 
investments are presently only in the 
range of US$100 to 200 million [37]. 
The amount that the impoverished 
populations of SSA could contribute 
towards these investments is negligible 
[36,37].
Unfortunately there is no ideal 
world. As sufﬁ  cient funds for 
high coverage provision of ACT 
are currently not available, an 
appropriate interim solution would 
be to use a pragmatic combination 
of two affordable drugs. The obvious 
choice would be the combination 
of pyrimethamine–sulfadoxine and 
amodiaquine, which has been shown to 
be as effective as ACT in a number of 
SSA countries, including Burkina Faso 
[38–40]. 
However, after it became clear 
that Burkina Faso would not receive 
GFATM funds for the purchase of 
ACT, the NMCP of Burkina Faso asked 
the World Bank to use a portion of an 
existing US$12 million loan from the 
Global Strategy and Booster Program to 
purchase pyrimethamine–sulfadoxine 
and amodiaquine as an interim 
solution. This request was rejected with 
the argument that WHO recommends 
only ACT. As a result, chloroquine 
remains factually the ﬁ  rst-line malaria 
treatment in Burkina Faso. These 
observations support the view that 
SSA countries continue to be victims 
of ignorance and lack of coordination 
between external donors and 
international organisations [41,42].
In summary, we call for more realistic 
malaria control policies and their rapid 
and comprehensive implementation 
in SSA. Too many African children 
are dying in these days from a disease 
against which effective and cost-
effective prevention and treatment 
options have long been developed.  
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